| Assessment Status | Rapid Review Complete |
| HTA ID | 24006 |
| Drug | Quizartinib |
| Brand | Vanflyta® |
| Indication | Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia that is FLT3-ITD positive. |
| Assessment Process | |
| Rapid review commissioned | 09/02/2024 |
| Rapid review completed | 11/03/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of quizartinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
